CEL-SCI Corporation to Present at the 13th Annual LD Micro Main Event Conference
December 14 2020 - 8:30AM
Business Wire
CEL-SCI Corporation (NYSE American: CVM), a Phase 3
cancer immunotherapy company, today announced that it will be
presenting at the 13th Annual LD Micro Main Event Conference on
Tuesday, December 15, 2020 at 10:00 a.m. ET. Geert Kersten, Chief
Executive Officer of CEL-SCI, will be presenting to a live virtual
audience.
CEL-SCI’s presentation will be broadcast live at
https://ve.mysequire.com/company?company_id=7413c04b-9bf8-491b-9f2a-88228de5695a
or on the Investor Relations section of CEL-SCI’s website at
cel-sci.com/new-investor-information/.
LD Micro’s Main Event will feature a new format, with companies
presenting for 10 minutes, followed by 10 minutes of Q&A by a
panel of investors and analysts.
View CEL-SCI’s profile here:
http://www.ldmicro.com/profile/CVM
About CEL-SCI Corporation
CEL-SCI believes that boosting a patient’s immune system while
it is still intact should provide the greatest possible impact on
survival. Therefore, in the Phase 3 study CEL-SCI treated patients
who are newly diagnosed with advanced primary squamous cell
carcinoma of the head and neck with the investigational product
Multikine* first, BEFORE they received surgery, radiation and/or
chemotherapy. This approach is unique. Most other cancer
immunotherapies are administered only after conventional therapies
have been tried and/or failed. Multikine (Leukocyte Interleukin,
Injection), has received Orphan Drug designation from the FDA for
neoadjuvant therapy in patients with squamous cell carcinoma
(cancer) of the head and neck.
CEL-SCI believes that this Phase 3 study is the largest Phase 3
study in the world for the treatment of head and neck cancer. Per
the study’s protocol, newly diagnosed patients with advanced
primary squamous cell carcinoma of the head and neck were treated
with the Multikine treatment regimen right after diagnosis and
prior to receiving the Standard of Care (SOC), which involves
surgery, radiation or concurrent radiochemotherapy. Multikine is
designed to help the immune system “see” the tumor at a time when
the immune system is still relatively intact and thereby thought to
better be able to mount an attack on the tumor. The aim of
treatment with Multikine is to boost the body’s immune system prior
to SOC to attack the cancer. The Phase 3 study is fully enrolled
with 928 patients and the last patient was treated in September
2016. To prove an overall survival benefit, the study requires
CEL-SCI to wait until 298 events have occurred among the two main
comparator groups. This study milestone occurred in late April
2020. The study is currently in the statistical analysis phase.
The Company’s LEAPS technology is being developed for rheumatoid
arthritis and as a potential treatment for COVID-19 infection. The
Company has operations in Vienna, Virginia, and near/in Baltimore,
Maryland.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, including statements with respect to Multikine and the
Phase 3 clinical trial of Multikine in patients with advanced
primary squamous cell carcinoma of the head and neck. When used in
this press release, the words "intends," "believes," "anticipated,"
"plans" and "expects," and similar expressions, are intended to
identify forward-looking statements. Such statements are subject to
risks and uncertainties that could cause actual results to differ
materially from those projected. Factors that could cause or
contribute to such differences include, an inability to duplicate
the clinical trials or nonclinical results demonstrated in clinical
studies, timely development of any potential products that can be
shown to be safe and effective, receiving necessary regulatory
approvals, difficulties in manufacturing any of the Company's
potential products, inability to raise the necessary capital and
the risk factors set forth from time to time in CEL-SCI's filings
with the Securities and Exchange Commission, including but not
limited to its report on Form 10-K/A for the year ended September
30, 2019. The Company undertakes no obligation to publicly release
the result of any revision to these forward-looking statements
which may be made to reflect the events or circumstances after the
date hereof or to reflect the occurrence of unanticipated
events.
* Multikine (Leukocyte Interleukin, Injection) is the trademark
that CEL-SCI has registered for this investigational therapy, and
this proprietary name is subject to FDA review in connection with
the Company's future anticipated regulatory submission for
approval. Multikine has not been licensed or approved for sale,
barter or exchange by the FDA or any other regulatory agency.
Similarly, its safety or efficacy has not been established for any
use. Moreover, no definitive conclusions can be drawn from the
early-phase, clinical-trials data involving the investigational
therapy Multikine. Further research is required, and early-phase
clinical trial results must be confirmed in the Phase 3 clinical
trial of this investigational therapy that is in progress.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201214005103/en/
Gavin de Windt CEL-SCI Corporation (703) 506-9460
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Sep 2023 to Sep 2024